Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Reyataz
REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 50
HOS-112180 · Präparat HOS-093615
If genotyping is not feasible,
full monitoring of safety and
efficacy should be performed.
Fluconazole 200 mg once Atazanavir and fluconazole concentrations No dosage adjustments are
daily were not significantly modified when needed for fluconazole and
(atazanavir 300 mg and REYATAZ/ritonavir was co-administered REYATAZ.
ritonavir 100 mg once daily) with fluconazole.
ANTIMYCOBACTERIAL
Rifabutin 150 mg twice Rifabutin AUC: ↑48% (↑19% ↑84%)** When given with REYATAZ,
weekly Rifabutin Cmax: ↑149% (↑103% ↑206%)** the recommended dose of
(atazanavir 300 mg and Rifabutin Cmin: ↑40% (↑5% ↑87%)** rifabutin is 150 mg 3 times per
ritonavir 100 mg once daily) week on set days (for example
25-O-desacetyl-rifabutin AUC: ↑990% Monday-Wednesday-Friday).
(↑714% ↑1 361%)** Increased monitoring for
25-O-desacetyl-rifabutin Cmax: ↑677% rifabutin-associated adverse
(↑513% ↑883%)** reactions including neutropenia
25-O-desacetyl-rifabutin Cmin: ↑1 045% and uveitis is warranted due to
(↑715% ↑1 510%)** an expected increase in
exposure to rifabutin. Further
**When compared to rifabutin 150 mg dosage reduction of rifabutin to
once daily alone. Total rifabutin and 150 mg twice weekly on set
25-O-desacetyl-rifabutin AUC: ↑119% days is recommended for
(↑78% ↑169%). patients in whom the 150 mg
dose 3 times per week is not
In previous studies, the pharmacokinetics tolerated. It should be kept in
of atazanavir was not altered by rifabutin. mind that the twice weekly
dosage of 150 mg may not
provide an optimal exposure to
rifabutin thus leading to a risk
of rifamycin resistance and a
treatment failure. No dose
adjustment is needed for
REYATAZ.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifabutin (HOS-086262) fluconazole (HOS-087945) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 8636d5f40f2d59b4431c4b6441a822c9757fee6002c3bac44d10a6c85c5838ba · Zeichen 27032–30282 im Abschnitt
Wechselwirkungen · Emselex
Emselex 7.5 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 4
HOS-113071 · Präparat HOS-093835
When co-administered with moderate CYP3A4 inhibitors such as erythromycin, clarithromycin,
telithromycin, fluconazole and grapefruit juice, the recommended starting dose of darifenacin should
be 7.5 mg daily. The dose may be titrated to 15 mg daily to obtain an improved clinical response
provided the dose is well tolerated. Darifenacin AUC24 and Cmax from 30 mg once daily dosing in
subjects who are extensive metabolisers were 95% and 128% higher when erythromycin (moderate
CYP3A4 inhibitor) was co-administered with darifenacin than when darifenacin was taken alone.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): grapefruit juice (HOS-088787) telithromycin (HOS-084523) fluconazole (HOS-087945) clarithromycin (HOS-084517) erythromycin (HOS-084514)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-15T12:10:00Z · SHA-256 de750767f67ad57bdc05ce4c855b9a1fcf428d24652a741d2de5aacfc4e7ad1c · Passage 464c1fab9226e851a3bf53f41068a2f130a46941e3523901d3193c58f9d61442 · Zeichen 1407–1978 im Abschnitt
Wechselwirkungen · Emselex
Emselex 15 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 14
HOS-113093 · Präparat HOS-093835
When co-administered with moderate CYP3A4 inhibitors such as erythromycin, clarithromycin,
telithromycin, fluconazole and grapefruit juice, the recommended starting dose of darifenacin should
be 7.5 mg daily. The dose may be titrated to 15 mg daily to obtain an improved clinical response
provided the dose is well tolerated. Darifenacin AUC24 and Cmax from 30 mg once-daily dosing in
subjects who are extensive metabolisers were 95% and 128% higher when erythromycin (moderate
CYP3A4 inhibitor) was co-administered with darifenacin than when darifenacin was taken alone.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): grapefruit juice (HOS-088787) telithromycin (HOS-084523) fluconazole (HOS-087945) clarithromycin (HOS-084517) erythromycin (HOS-084514)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-15T12:10:00Z · SHA-256 de750767f67ad57bdc05ce4c855b9a1fcf428d24652a741d2de5aacfc4e7ad1c · Passage 571ea727acfa76726808c203962299cfb09288a48416a3433d5d091ab46f0065 · Zeichen 1407–1978 im Abschnitt
Wechselwirkungen · Procoralan
Procoralan 5 mg film-coated tablets Procoralan 7.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-113861 · Präparat HOS-093985
Moderate CYP3A4 inhibitors
The concomitant use of ivabradine with other moderate CYP3A4 inhibitors (e.g. fluconazole) may be
considered at the starting dose of 2.5 mg twice daily and if resting heart rate is above 70 bpm, with
monitoring of heart rate.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fluconazole (HOS-087945)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-17T17:49:00Z · SHA-256 603a04f5264f2cd02119b9fdddd8869a5b599fbe491c4482b048613e56f12c88 · Passage f79f482b04a2c26ff26d09726b71cff4e724a7e6af1dafa78083e3e238b6a510 · Zeichen 3006–3258 im Abschnitt
Wechselwirkungen · Corlentor
Corlentor 5 mg film-coated tablets Corlentor 7.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-113896 · Präparat HOS-093993
The concomitant use of ivabradine with other moderate CYP3A4 inhibitors (e.g. fluconazole) may be
considered at the starting dose of 2.5 mg twice daily and if resting heart rate is above 70 bpm, with
monitoring of heart rate.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fluconazole (HOS-087945)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-17T17:03:00Z · SHA-256 d87e68351dedcde32d83ee33c2f0d9205f341c44bb5b4d122f4a04ffba50a0e0 · Passage 1a1c7b8cf9134d8340ff5d7caa0363c94d1e831dcce186bd8041f2953546fd03 · Zeichen 3034–3259 im Abschnitt
Wechselwirkungen · Aptivus
Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 13
HOS-114818 · Präparat HOS-094169
Pharmacokinetic enhancer
Cobicistat and cobicistat- When co-administered, tipranavir Aptivus/ritonavir should not be
containing products and cobicistat exposures are administered concomitantly with
markedly lower compared to that cobicistat or cobicistat-containing
of tipranavir when boosted with products.
low dose ritonavir.
Antifungals
Fluconazole 200 mg QD Fluconazole ↔ No dosage adjustments are
(Day 1) then 100 mg QD recommended. Fluconazole doses
Tipranavir Cmax ↑ 32% > 200 mg/day are not
Tipranavir AUC ↑ 50% recommended.
Tipranavir Cmin ↑ 69%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cobicistat (HOS-088111) fluconazole (HOS-087945) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T09:35:00Z · SHA-256 1c396190f98e89933229f2261b0e436bd43dac9c1de8e2dacaa36a755dc06dce · Passage 549670a9ca1f43609bd832a4fb930f3c15098cf3b9b9023af5a21f53c645bcbb · Zeichen 18330–19175 im Abschnitt
Wechselwirkungen · Tandemact
Tandemact 30 mg/2 mg tablets Tandemact 30 mg/4 mg tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-115620 · Präparat HOS-094329
phenylbutazone, azapropazone and oxyfenbutazone
insulin and oral antidiabetic products
metformin
salicylates and p-amino-salicylic acid
anabolic steroids and male sex hormones
chloramphenicol
clarithromycin
coumarin anticoagulants
disopyramide
fenfluramine
fibrates
angiotensin-converting enzyme (ACE) inhibitors
fluoxetine
allopurinol
sympatholytics
cyclo-, tro- and iphosphamides
sulphinpyrazone
certain long-acting sulphonamides
tetracyclines
MAO-inhibitors
quinolone antibiotics
probenecid
miconazole
pentoxyfylline (high dose parenteral)
tritoqualine
fluconazole
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): allopurinol (HOS-089178) fenfluramine (HOS-115627) coumarin (HOS-088372) salicylic acid (HOS-088803) disopyramide (HOS-085595) fluconazole (HOS-087945) clarithromycin (HOS-084517) probenecid (HOS-085208) tritoqualine (HOS-115631) fluoxetine (HOS-085946) chloramphenicol (HOS-115623) phenylbutazone (HOS-110030) metformin (HOS-091032) miconazole (HOS-115630)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-09-13T13:32:00Z · SHA-256 2f687843aaa08f3b2b5add2ddc427b0f290d7d4b353b767838c175de06dc93d0 · Passage 13c963df033e1d82daa0a85cebdc18e8520390310b9bac096c6bc28f121fb103 · Zeichen 2312–2879 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 17–18
HOS-116378 · Präparat HOS-094447
17
ANTI-DIABETICS
Metformin Not studied. Based on theoretical Careful patient monitoring and
considerations PREZISTA dose adjustment of metformin is
co-administered with cobicistat is recommended in patients who are
expected to increase metformin plasma taking PREZISTA co-administered
concentrations. with cobicistat.
(MATE1 inhibition) (not applicable for PREZISTA
co-administered with ritonavir)
ANTIEMETICS
Domperidone Not studied. Co-administration of domperidone
with boosted PREZISTA is
contraindicated.
ANTIFUNGALS
Voriconazole Not studied. Ritonavir may decrease Voriconazole should not be
plasma concentrations of voriconazole. combined with boosted
(induction of CYP450 enzymes) PREZISTA unless an assessment
of the benefit/risk ratio justifies the
Concentrations of voriconazole may use of voriconazole.
increase or decrease when
co-administered with PREZISTA
co-administered with cobicistat.
(inhibition of CYP450 enzymes)
Fluconazole Not studied. Boosted PREZISTA may Caution is warranted and clinical
Isavuconazole increase antifungal plasma concentrations monitoring is recommended. When
Itraconazole and posaconazole, isavuconazole, co-administration is required the
Posaconazole itraconazole or fluconazole may increase daily dose of itraconazole should
darunavir concentrations. not exceed 200 mg.
(CYP3A and/or P-gp inhibition)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): isavuconazole (HOS-085186) cobicistat (HOS-088111) domperidone (HOS-114656) voriconazole (HOS-084524) itraconazole (HOS-084516) fluconazole (HOS-087945) ritonavir (HOS-084521) posaconazole (HOS-085622) metformin (HOS-091032)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 5307db9d59d8efdd7ae524944aa157f963cc375ad8c53e1296ceb7c11992bc47 · Zeichen 40055–42401 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 59
HOS-116522 · Präparat HOS-094447
Concomitant use of PREZISTA Clinical monitoring is
co-administered with low dose ritonavir recommended when
and these antidepressants may increase co-administering PREZISTA with
concentrations of the antidepressant. low dose ritonavir with these
(CYP2D6 and/or CYP3A inhibition) antidepressants and a dose
adjustment of the antidepressant
Amitriptyline may be needed.
Desipramine
Imipramine
Nortriptyline
Trazodone
ANTIEMETICS
Domperidone Not studied. Co-administration of domperidone
with boosted PREZISTA is
contraindicated.
ANTIFUNGALS
Voriconazole Not studied. Ritonavir may decrease Voriconazole should not be
plasma concentrations of voriconazole. combined with PREZISTA
(induction of CYP450 enzymes) co-administered with low dose
ritonavir unless an assessment of
the benefit/risk ratio justifies the
use of voriconazole.
Fluconazole Not studied. PREZISTA may increase Caution is warranted and clinical
Isavuconazole antifungal plasma concentrations and monitoring is recommended. When
Itraconazole posaconazole, isavuconazole, co-administration is required the
Posaconazole itraconazole, or fluconazole may increase daily dose of itraconazole should
darunavir concentrations. not exceed 200 mg.
(CYP3A and/or P-gp inhibition)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): isavuconazole (HOS-085186) nortriptyline (HOS-086245) amitriptyline (HOS-085911) desipramine (HOS-086249) imipramine (HOS-085907) domperidone (HOS-114656) voriconazole (HOS-084524) itraconazole (HOS-084516) trazodone (HOS-086251) fluconazole (HOS-087945) ritonavir (HOS-084521) posaconazole (HOS-085622)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 22f4e74ad4f26762902abfc0033ac15b80ded8bd1a23d2f6a966a8c972097288 · Zeichen 30842–32867 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 99–100
HOS-116613 · Präparat HOS-094447
99
ANTIEMETICS
Domperidone Not studied. Co-administration of domperidone
with boosted PREZISTA is
contraindicated.
ANTIFUNGALS
Voriconazole Not studied. Ritonavir may decrease Voriconazole should not be
plasma concentrations of voriconazole. combined with boosted
(induction of CYP450 enzymes) PREZISTA unless an assessment
of the benefit/risk ratio justifies the
Concentrations of voriconazole may use of voriconazole.
increase or decrease when
co-administered with PREZISTA
co-administered with cobicistat.
(inhibition of CYP450 enzymes)
Fluconazole Not studied. Boosted PREZISTA may Caution is warranted and clinical
Isavuconazole increase antifungal plasma concentrations monitoring is recommended.
Itraconazole and posaconazole, isavuconazole, When co-administration is
Posaconazole itraconazole or fluconazole may increase required the daily dose of
darunavir concentrations. itraconazole should not exceed
(CYP3A and/or P-gp inhibition) 200 mg.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): isavuconazole (HOS-085186) cobicistat (HOS-088111) domperidone (HOS-114656) voriconazole (HOS-084524) itraconazole (HOS-084516) fluconazole (HOS-087945) ritonavir (HOS-084521) posaconazole (HOS-085622)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 13c8fc0fe58788a9eb15a4ab6e0e9fb34c04f3bc6ed970d671cb11cef0f8bb26 · Zeichen 40236–41872 im Abschnitt
Wechselwirkungen · Advagraf
Advagraf 0.5 mg prolonged-release hard capsules Advagraf 1 mg prolonged-release hard capsules Advagraf 3 mg prolonged-release hard capsules Advagraf 5 mg prolonged-release hard capsules · Abschnitt 4.5 · PDF-Seite 10–11
HOS-116802 · Präparat HOS-094481
10
Drug/Substance Class or Drug interaction effect Recommendations concerning
Name co-administration
Strong CYP3A4 inhibitors: May increase tacrolimus whole It is recommended that
antifungal agents (e.g., blood trough concentrations and concomitant use should be
ketoconazole, itraconazole, increase the risk of serious adverse avoided. If co-administration
posaconazole, voriconazole), reactions (e.g., nephrotoxicity, of a strong CYP3A4 inhibitor
the macrolide antibiotics neurotoxicity, QT prolongation) is unavoidable, consider
(e.g., telithromycin, which requires close monitoring omitting the dose of tacrolimus
troleandomycin, [see section 4.4]. the day the strong CYP3A4
clarithromycin, josamycin), Rapid and sharp increases in inhibitor is initiated. Reinitiate
HIV protease inhibitors tacrolimus levels may occur, as tacrolimus the next day at a
(e.g., ritonavir, nelfinavir, early as within 1-3 days after co- reduced dose based on
saquinavir), HCV protease administration, despite immediate tacrolimus blood
inhibitors (e.g., telaprevir, reduction of tacrolimus dose. concentrations. Changes in
boceprevir, and the Overall tacrolimus exposure may both tacrolimus dose and/or
combination of ombitasvir increase > 5 fold. When ritonavir dosing frequency should be
and paritaprevir with combinations are co-administered, individualized and adjusted as
ritonavir, when used with tacrolimus exposure may increase needed based on tacrolimus
and without dasabuvir), > 50 fold. Nearly all patients may trough concentrations, which
nefazodone, the require a reduction in tacrolimus should be assessed at initiation,
pharmacokinetic enhancer dose and temporary interruption of monitored frequently
cobicistat, and the kinase tacrolimus may also be necessary. throughout (starting within the
inhibitors idelalisib, The effect on tacrolimus blood first few days) and re-
ceritinib. concentrations may remain for evaluated on and after
Strong interactions have also several days after co-administration completion of the CYP3A4
been observed with the is completed. inhibitor. Upon completion,
macrolide antibiotic appropriate dose and dosing
erythromycin frequency of tacrolimus should
be guided by tacrolimus blood
concentrations. Monitor renal
function, ECG for QT
prolongation, and other side
effects closely.
Moderate or weak CYP3A4 May increase tacrolimus whole Monitor tacrolimus whole
inhibitors: blood trough concentrations and blood trough concentrations
antifungal agents (e.g., increase the risk of serious adverse frequently, starting within the
fluconazole, isavuconazole, reactions (e.g., neurotoxicity, QT first few days of co-
clotrimazole, miconazole), prolongation) [see section 4.4]. A administration. Reduce
the macrolide antibiotics rapid increase in tacrolimus level tacrolimus dose if needed [see
(e.g., azithromycin), calcium may occur. section 4.2]. Monitor renal
channel blockers (e.g., function, ECG for QT
nifedipine, nicardipine, prolongation, and other side
diltiazem, verapamil), effects closely.
amiodarone, danazol,
ethinylestradiol,
lansoprazole, omeprazole,
the HCV antivirals
elbasvir/grazoprevir and
glecaprevir/pibrentasvir, the
CMV antiviral letermovir,
and the tyrosine kinase
inhibitors nilotinib,
crizotinib and imatinib and
(Chinese) herbal remedies
containing extracts of
Schisandra sphenanthera
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) letermovir (HOS-090621) ceritinib (HOS-086215) josamycin (HOS-113844) diltiazem (HOS-086288) nefazodone (HOS-084519) elbasvir (HOS-108814) isavuconazole (HOS-085186) nifedipine (HOS-086289) nelfinavir (HOS-084520) nicardipine (HOS-090619) protease (HOS-085623) ketoconazole (HOS-084513) pibrentasvir (HOS-086298) crizotinib (HOS-116818) cobicistat (HOS-088111) glecaprevir (HOS-086297) azithromycin (HOS-088112) clotrimazole (HOS-090574) calcium (HOS-085615) imatinib (HOS-110212) dasabuvir (HOS-110302) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) grazoprevir (HOS-108815) itraconazole (HOS-084516) saquinavir (HOS-084522) danazol (HOS-085473) fluconazole (HOS-087945) ombitasvir (HOS-110300) boceprevir (HOS-090617) clarithromycin (HOS-084517) erythromycin (HOS-084514) troleandomycin (HOS-090575) ritonavir (HOS-084521) amiodarone (HOS-085596) paritaprevir (HOS-110301) tyrosine (HOS-108875) posaconazole (HOS-085622) nilotinib (HOS-086218) miconazole (HOS-115630) idelalisib (HOS-116811) omeprazole (HOS-085912) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-02-27T10:10:00Z · SHA-256 0ed42bc08ffe6bd7e6c8ed94445bdb8b8c9971dabe41ef3a899ec75fc2f97c0e · Passage 871fa2c72a31ddd6873cbb2f1b3b0dd9ad898b46eba141ac32a052a178cc3bc9 · Zeichen 3910–8415 im Abschnitt
Wechselwirkungen · Toviaz
TOVIAZ 4 mg prolonged-release tablets TOVIAZ 8 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-117261 · Präparat HOS-094561
Moderate CYP3A4 inhibitors
Following blockade of CYP3A4 by coadministration of the moderate CYP3A4 inhibitor fluconazole
200 mg twice a day for 2 days, Cmax and AUC of the active metabolite of fesoterodine increased
approximately 19% and 27%, respectively. No dosing adjustments are recommended in the presence
of moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole, diltiazem, verapamil and grapefruit
juice).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) fluconazole (HOS-087945) erythromycin (HOS-084514) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-04T15:52:00Z · SHA-256 c9fd9fb2f6c8ee3d5e56c913ba09d40147211dee6df16329539fa6b5e813accb · Passage 0e33e67cc3f7d7f2be5a7558d50a2d9368bd2f75b7ecea69b873e1745c8d96d3 · Zeichen 1522–1940 im Abschnitt
Wechselwirkungen · Mycamine
Mycamine 50 mg powder for concentrate for solution for infusion Mycamine 100 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 5
HOS-117345 · Präparat HOS-094585
Drug interaction studies in healthy human subjects were conducted to evaluate the potential for
interaction between micafungin and mycophenolate mofetil, ciclosporin, tacrolimus, prednisolone,
sirolimus, nifedipine, fluconazole, ritonavir, rifampicin, itraconazole, voriconazole and amphotericin
B. In these studies, no evidence of altered pharmacokinetics of micafungin was observed. No
micafungin dose adjustments are necessary when these medicines are administered concomitantly.
Exposure (AUC) of itraconazole, sirolimus and nifedipine was slightly increased in the presence of
micafungin (22%, 21% and 18% respectively).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): prednisolone (HOS-086337) nifedipine (HOS-086289) amphotericin (HOS-088524) voriconazole (HOS-084524) itraconazole (HOS-084516) fluconazole (HOS-087945) tacrolimus (HOS-085202) sirolimus (HOS-085172) ritonavir (HOS-084521) mycophenolate mofetil (HOS-085154)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-04T14:40:00Z · SHA-256 b10a8e41df9b387a8b080f2a96c5684a6a8901efa78aaf4c99c300096afa4cf9 · Passage cbe82a5c8fc5ae28a4114fd1888efec3a0d481da438e2fa59ffb5442277ef92b · Zeichen 105–730 im Abschnitt
Wechselwirkungen · Yondelis
Yondelis 0.25 mg powder for concentrate for solution for infusion. Yondelis 1 mg powder for concentrate for solution for infusion. · Abschnitt 4.5 · PDF-Seite 7
HOS-117690 · Präparat HOS-094673
When ketoconazole was co-administered with trabectedin, the plasma exposure of trabectedin was
increased by approximately 21% for Cmax and 66% for AUC, but no new safety concerns were
identified. Close monitoring of toxicities is required in patients receiving trabectedin in combination
with potent CYP3A4 inhibitors (e.g. oral ketoconazole, fluconazole, ritonavir, clarithromycin or
aprepitant) and such combinations should be avoided if possible. If such combinations are needed,
appropriate dose adjustments should be applied in the event of toxicities (see sections 4.2 and 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) aprepitant (HOS-112506) fluconazole (HOS-087945) clarithromycin (HOS-084517) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-20T12:25:00Z · SHA-256 ded6c974c7b3e49daa849909bad6cd80ddbd0729d218225406a5eca97ec9420a · Passage 728cfacefea374bf1371a728308eb13a3c9d98e33c49e7adb2580957c6e01135 · Zeichen 643–1227 im Abschnitt
Wechselwirkungen · Ranexa (previously Latixa)
Ranexa 375 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 4
HOS-118249 · Präparat HOS-094791
Diltiazem (180 to 360 mg once daily), a moderately potent CYP3A4 inhibitor, causes dose-dependent
increases in average ranolazine steady-state concentrations of 1.5- to 2.4-fold. Careful dose titration of
Ranexa is recommended in patients treated with diltiazem and other moderately potent CYP3A4
inhibitors (e.g. erythromycin, fluconazole). Down-titration of Ranexa may be required (see sections
4.2 and 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) fluconazole (HOS-087945) erythromycin (HOS-084514)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-11T13:07:00Z · SHA-256 0a3c1ac3a3e7045516969928ccd0918506379303d254770ac2a2d732c1bd1d40 · Passage 5f1bf08df6b80c8684291b05050b0155b15cfd1eb5db3de338f178e7722e96a7 · Zeichen 732–1142 im Abschnitt
Wechselwirkungen · Ranexa (previously Latixa)
Ranexa 500 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 16
HOS-118296 · Präparat HOS-094791
Diltiazem (180 to 360 mg once daily), a moderately potent CYP3A4 inhibitor, causes dose-dependent
increases in average ranolazine steady-state concentrations of 1.5- to 2.4-fold. Careful dose titration of
Ranexa is recommended in patients treated with diltiazem and other moderately potent CYP3A4
inhibitors (e.g. erythromycin, fluconazole). Down-titration of Ranexa may be required (see sections
4.2 and 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) fluconazole (HOS-087945) erythromycin (HOS-084514)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-11T13:07:00Z · SHA-256 0a3c1ac3a3e7045516969928ccd0918506379303d254770ac2a2d732c1bd1d40 · Passage 5f1bf08df6b80c8684291b05050b0155b15cfd1eb5db3de338f178e7722e96a7 · Zeichen 732–1142 im Abschnitt
Wechselwirkungen · Ranexa (previously Latixa)
Ranexa 750 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 28
HOS-118338 · Präparat HOS-094791
Diltiazem (180 to 360 mg once daily), a moderately potent CYP3A4 inhibitor, causes dose-dependent
increases in average ranolazine steady-state concentrations of 1.5- to 2.4-fold. Careful dose titration of
Ranexa is recommended in patients treated with diltiazem and other moderately potent CYP3A4
inhibitors (e.g. erythromycin, fluconazole). Down-titration of Ranexa may be required (see sections
4.2 and 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) fluconazole (HOS-087945) erythromycin (HOS-084514)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-11T13:07:00Z · SHA-256 0a3c1ac3a3e7045516969928ccd0918506379303d254770ac2a2d732c1bd1d40 · Passage 5f1bf08df6b80c8684291b05050b0155b15cfd1eb5db3de338f178e7722e96a7 · Zeichen 732–1142 im Abschnitt
Wechselwirkungen · Celsentri
CELSENTRI 150 mg film-coated tablets CELSENTRI 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12
HOS-118469 · Präparat HOS-094825
Concomitant use of
CELSENTRI and
fosamprenavir/ritonavir is
not recommended.
Clarithromycin, Not studied, but both are potent CELSENTRI dose should
Telithromycin CYP3A4 inhibitors and would be be decreased to 150 mg
expected to increase maraviroc twice daily when
concentrations. co-administered with
clarithromycin and
telithromycin.
ANTICONVULSANTS
Carbamezepine, Not studied, but these are potent CELSENTRI dose should
Phenobarbital, CYP3A4 inducers and would be be increased to 600 mg
Phenytoin expected to decrease maraviroc twice daily when co-
concentrations. administered with
carbamazepine,
phenobarbital or
phenytoin in the absence
of a potent CYP3A4
inhibitor.
ANTIFUNGALS
Ketoconazole 400 mg QD Maraviroc AUCtau: ↑ 5.00 CELSENTRI dose should
(maraviroc 100 mg BID) Maraviroc Cmax: ↑ 3.38 be decreased to 150 mg
Ketoconazole concentrations not twice daily when
measured, no effect is expected. co-administered with
ketoconazole.
Itraconazole Not studied. Itraconazole, is a potent CELSENTRI dose should
CYP3A4 inhibitor and would be be decreased to 150 mg
expected to increase the exposure of twice daily when
maraviroc. co-administered with
itraconazole.
Fluconazole Fluconazole is considered to be a CELSENTRI 300 mg
moderate CYP3A4 inhibitor. twice daily should be
Population PK studies suggest that a administered with caution
dose adjustment of maraviroc is not when co-administered
required. with fluconazole.
ANTIVIRALS
Anti-HBV
Pegylated interferon Pegylated interferon has not been CELSENTRI 300 mg
studied, no interaction is expected. twice daily and pegylated
interferon can be
co-administered without
dose adjustment.
Anti-HCV
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) ketoconazole (HOS-084513) carbamazepine (HOS-085618) telithromycin (HOS-084523) itraconazole (HOS-084516) fluconazole (HOS-087945) clarithromycin (HOS-084517) fosamprenavir (HOS-086182) ritonavir (HOS-084521) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-12T15:51:00Z · SHA-256 af7f0c7bbfd6e612d5a885c59ba9795f11ee85b00c3e0504de2a206af5fbec72 · Passage 1d5347b247b278d8c4adf916ef615f4e2f029d5988565ee48d79ce9fbe1e5087 · Zeichen 17223–20590 im Abschnitt
Wechselwirkungen · Celsentri
CELSENTRI 20 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 38–39
HOS-118509 · Präparat HOS-094825
38
Fluconazole Fluconazole is considered to be a CELSENTRI 300 mg twice
moderate CYP3A4 inhibitor. daily should be administered
Population PK studies suggest that a with caution when
dose adjustment of maraviroc is not co-administered with
required. fluconazole.
ANTIVIRALS
Anti-HBV
Pegylated interferon Pegylated interferon has not been CELSENTRI 300 mg twice
studied, no interaction is expected. daily and pegylated interferon
can be co-administered
without dose adjustment.
Anti-HCV
Ribavirin Ribavirin has not been studied, no CELSENTRI 300 mg twice
interaction is expected. daily and ribavirin can be
co-administered without dose
adjustment.
DRUG ABUSE
Methadone Not studied, no interaction expected. CELSENTRI 300 mg twice
daily and methadone can be
co-administered without dose
adjustment.
Buprenorphine Not studied, no interaction expected. CELSENTRI 300 mg twice
daily and buprenorphine can
be co-administered without
dose adjustment.
LIPID LOWERING
MEDICINAL PRODUCTS
Statins Not studied, no interaction expected. CELSENTRI 300 mg twice
daily and statins can be
co-administered without dose
adjustment.
ANTIARRHYTHMICS
Digoxin 0.25 mg Digoxin. AUCt: ↔ 1.00 CELSENTRI 300 mg twice
Single Dose Digoxin. Cmax: ↔ 1.04 daily and digoxin can be
(maraviroc 300 mg BID) Maraviroc concentrations not co-administered without dose
measured, no interaction expected. adjustment.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methadone (HOS-086198) digoxin (HOS-086172) buprenorphine (HOS-086193) ribavirin (HOS-088127) fluconazole (HOS-087945)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-12T15:51:00Z · SHA-256 af7f0c7bbfd6e612d5a885c59ba9795f11ee85b00c3e0504de2a206af5fbec72 · Passage 65bf52b9ee65912983f669222a3e491b48e145986d852cfa5f6db174e1752c72 · Zeichen 18880–21635 im Abschnitt
Wechselwirkungen · Effentora
Effentora 100 micrograms buccal tablets Effentora 200 micrograms buccal tablets Effentora 400 micrograms buccal tablets Effentora 600 micrograms buccal tablets Effentora 800 micrograms buccal tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-209208 · Präparat HOS-154273
CYP3A4 inhibitors
The concomitant use of Effentora with strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole,
itraconazole, troleandomycin, clarithromycin, and nelfinavir) or moderate CYP3A4 inhibitors (e.g.,
amprenavir, aprepitant, diltiazem, erythromycin, fluconazole, fosamprenavir, grapefruit juice, and
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) nelfinavir (HOS-084520) ketoconazole (HOS-084513) aprepitant (HOS-112506) grapefruit juice (HOS-088787) itraconazole (HOS-084516) fluconazole (HOS-087945) clarithromycin (HOS-084517) erythromycin (HOS-084514) amprenavir (HOS-086183) troleandomycin (HOS-090575) fosamprenavir (HOS-086182) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T10:58:00Z · SHA-256 b4a304bd9d2ca3f423d95be522ff20307f46a2ce762379e94c21a56805a240f8 · Passage 0cf5c88c70c4ae39f0d76035db9f738e3de8f9e72008c3bf601dfee4d384ee76 · Zeichen 359–669 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.